Overview

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy (% response) of epoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer.
Details
Lead Sponsor:
Janssen-Cilag B.V.
Treatments:
Epoetin Alfa